Summary: Genmab A/S increases its share capital by 131,541 shares as a
result of employee warrant exercise.
Copenhagen, Denmark; June 1, 2007 - Genmab A/S (CSE: GEN) has decided to
increase its share capital by 131,541 shares as a consequence of the exercise of
employee warrants.
The increase is effected without any preemption rights for the existing
shareholders of the company or others. The shares are subscribed in cash at the
following prices per share of nominally DKK 1: 47,995 shares at DKK 33.70,
23,450 shares at DKK 37.00, 12,975 shares at DKK 62.50, 6,125 shares at DKK
86.00, 6,000 shares at DKK 89.50, 1,125 shares at DKK 97.00, 2,875 shares at DKK
101.00, 7,311 shares at DKK 116.00, 625 shares at DKK 130.00, 13,625 shares at
DKK 139.50, 3,849 shares at DKK 184.00 and 5,586 shares at DKK 210.50. Proceeds
to the company are approximately DKK 9.5 million (approx. USD 1.7 million). The
increase corresponds to approx. 0.30 % of the company's share capital.
The new shares are ordinary shares without any special rights and are freely
transferable negotiable instruments. The new shares shall give rights to
dividends and other rights in relation to the company as of subscription, i.e.
inter alia full rights to dividends for the financial year 2007. The new shares
will be listed on the Copenhagen Stock Exchange after registration with the
Danish Commerce and Companies Agency. Genmab A/S' current share capital amounts
to DKK 44,333,015 and will after the capital increase be DKK 44,464,556. The
capital increase is expected to be finalized shortly.
About Genmab A/S
Genmab A/S is a biotechnology company that creates and develops human antibodies
for the treatment of life-threatening and debilitating diseases. Genmab has
numerous products in development to treat cancer, infectious disease, rheumatoid
arthritis and other inflammatory conditions, and intends to continue assembling
a broad portfolio of new therapeutic products. In addition, Genmab has developed
UniBody(TM), a new proprietary technology that creates a stable, smaller
antibody format. Genmab has operations in Europe and the US. For more
information about Genmab, visit www.genmab.com.
This press release contains forward looking statements. The words “believe”,
“expect”, “anticipate”, “intend” and “plan” and similar expressions identify
forward looking statements. Actual results or performance may differ materially
from any future results or performance expressed or implied by such statements.
The important factors that could cause our actual results or performance to
differ materially include, among others, risks associated with product discovery
and development, uncertainties related to the outcome and conduct of clinical
trials including unforeseen safety issues, uncertainties related to product
manufacturing, the lack of market acceptance of our products, our inability to
manage growth, the competitive environment in relation to our business area and
markets, our inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and proprietary rights,
our relationships with affiliated entities, changes and developments in
technology which may render our products obsolete, and other factors. Genmab is
not under an obligation to up-date statements regarding the future following the
publication of this release; nor to confirm such statements in relation to
actual results, unless this is required by law.
Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R);
HuMax-EGFr(TM); HuMax-Inflam(TM); HuMax-TAC(TM); HuMax-HepC(TM), HuMax-CD38(TM);
HuMax-ZP3(TM); and UniBody(TM) are all trademarks of Genmab A/S.
Contact: Helle Husted, Sr. Director, Investor Relations, T: +45 33 44 77 30, M:
+45 25 27 47 13, E: hth@genmab.com
Stock Exchange Release no. 23/2007
